SCHEMBL6306155

SCHEMBL6306155

COc1ccc2c(c1)C(c1cccc(Cl)c1)CCC2

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GID4 Q8IVV7 1/20 0.64
KDM1A O60341 5/20 0.52
MAOA P21397 5/20 0.52
MAOB P27338 5/20 0.52
CHRNA7 P36544 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
DRD2 P14416 2/20 0.43
DRD4 P21917 2/20 0.43
CYP19A1 P11511 2/20 0.41
CYP11B1 P15538 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20856195 0.91 GID4 (0.66) GID4KDM1AMAOAMAOBCHRNA7
SCHEMBL28603159 0.85 KDM1A (0.55) GID4KDM1AMAOAMAOBCHRNA7
SCHEMBL6306064 0.85 GID4 (0.68) GID4KDM1AMAOAMAOBCHRNA7
SCHEMBL28596328 0.82 GID4 (0.59) GID4KDM1AMAOAMAOBCHRNA7
SCHEMBL28596345 0.79 GID4 (0.56) GID4KDM1AMAOAMAOBCHRNA7
SCHEMBL20863607 0.79 GID4 (1.00) GID4KDM1AMAOAMAOB
SCHEMBL17274560 0.78 HTR2A (0.47) KDM1AMAOAMAOBSLC6A2SLC6A4
SCHEMBL6300145 0.78 DDB1 (0.46) GID4KDM1AMAOAMAOBCYP19A1
SCHEMBL17274561 0.78 HTR2A (0.47) KDM1AMAOAMAOBSLC6A2SLC6A4
SCHEMBL17274558 0.78 HTR2A (0.47) KDM1AMAOAMAOBSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108794308-B 1,2,3, 4-tetrahydronaphthalene compound and preparation method and application thereof 北京大学深圳研究生院 2021-07-20 CN disclosed
US-6943183-B2 5-substituted tetralones as inhibitors of ras farnesyl transferase PFIZER INC (US) 2005-09-13 US disclosed
US-20040044057-A1 5- substituted tetralones as inhibitors of ras farnesyl trransferase WARNER-LAMBERT COMPANY 2004-03-04 US disclosed
EP-1276725-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2003-01-22 EP disclosed
WO-2001079180-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044057-A1 5- substituted tetralones as inhibitors of ras farnesyl trransferase PTAR1, FNTA, GGPS1 GID4 1034/4885KDM1A 3120/4885MAOA 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.